Randomized, open label, multicentre phase III study of efficacy and safety in polycythermia versus subjects who are resilient to or intolerant of hydroxyurea: JAK inhibitor INC424 tablets versus best available care - Porth Ymchwil

Ewch i'r Pennawd Ewch i'r Dudalen Lywio Ewch i'r Cynnwys Ewch i'r Troednodyn

Teitl: Randomized, open label, multicentre phase III study of efficacy and safety in polycythermia versus subjects who are resilient to or intolerant of hydroxyurea: JAK inhibitor INC424 tablets versus best available care

Arianwyr
Novartis Pharmaceuticals UK Ltd

Prif Ymchwiliwr

Knapper, Steven

Manylion y Prosiect

Gwerth net y ffigur a ddyfarnwyd i Brifysgol Caerdydd: £3,795.00

Dyddiad dechrau: 30.03.2011

Dyddiad gorffen: 31.03.2017